A Phase 4 interventional study of Peginterferon alfa-2b (SCH 054031) and Ribavirin (SCH 018908) in Hepatitis C, Chronic, Hepacivirus and HIV Infections, sponsored by Merck Sharp & Dohme LLC. Terminated. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-04-06.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2b · Hepatitis C, Chronic.
Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, this one is the 34th largest by enrollment of the 39 interventional ones that give a count, is one of 8 that started in 2005, is one of 10 in phase 4, and was the 21st registered.
950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.
Browse Hepatitis C, Chronic studies →None of the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →
peginterferon alfa-2b: first FDA approval 2001 (PEGINTRON), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →
Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 8 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 11 is below the median of 90 across 696 interventional studies indexed under Hepatitis C, Chronic.
Median enrollment 99 across the 39 interventional studies. Of the 35 that completed or were terminated, 21 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
110 studies in Hepatitis C, Chronic by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 106 finished, 81 (76%) have results posted.
Among the 110 studies in Hepatitis C, Chronic by Merck & Co., Inc, this one is the 68th largest by enrollment of the 72 interventional ones that give a count, is one of 24 that started in 2005, is one of 8 in phase 4, and was the 23rd registered.
Merck & Co., Inc’s Hepatitis C, Chronic studies by the year they started, since 2002.
None of the studies under way reaches primary completion within a year.
Among the 40 studies testing peginterferon alfa-2b in Hepatitis C, Chronic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 110 in Hepatitis C, Chronic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
In this study, adult Indonesian subjects with human immunodeficiency virus (HIV) coinfected with chronic hepatitis C (CHC) will be given peginterferon alfa-2b (PEG-IFN) plus ribavirin (RBV) combination therapy. The efficacy rate (sustained virologic response, end of treatment virologic response, and sustained biochemical response), the subject morbidity rate as caused by other opportunistic infection (eg, bacterial pneumonia, tuberculosis, and other bacterial infection), and the safety and tolerability of this combination therapy will be examined.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Washout period
A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PEG-IFN + RBV therapy in previously untreated chronic HCV subjects coinfected with HIV
Biological: Peginterferon alfa-2b (SCH 054031) · Drug: Ribavirin (SCH 018908)
Subjects will be given peginterferon alfa-2b (PEG-IFN) subcutaneously, at a dose of 1.5 ug/kg weekly. Treatment duration will be 48 weeks for subjects with Hepatitis C Virus (HCV) genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline Hepatitis C Virus-ribonucleic acid (HCV-RNA) below 800,000 IU/mL.
Also known as: PegIntron
Subjects will be given ribavirin 800 mg/day orally(PO) when body weight is \<65 kg, 1000 mg/day when body weight is between 65 kg and 85 kg, and 1200 mg/day when body weight is \>85 kg. Treatment duration will be 48 weeks for subjects with HCV genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline HCV-RNA below 800,000 IU/mL.
Also known as: Rebetol
Number of Participants Who Achieved Sustained Virologic Response (SVR)
Treatment duration for genotype 1 participants was 48 weeks. Treatment duration for genotypes 2 \& 3 participants who had baseline hepatitis c virus ribonucleic acid \[HCV-RNA\] \<800,000 IU/mL was 24 weeks. SVR was defined as plasma HCV RNA level below lower level of quanitation at the end of 24 weeks follow-up (week 48 or 72). The study was terminated due to low enrollment. This analysis was not performed.
Time frame: Week 48 or Week 72 (depending on duration of treatment)
Number of Participants Who Achieved Virologic Response (VR)
Treatment duration for genotype 1 participants was 48 weeks. Treatment duration for genotypes 2 \& 3 participants who had baseline hepatitis c virus ribonucleic acid \[HCV-RNA\] \<800,000 IU/mL was 24 weeks. The study was terminated due to low enrollment. This analysis was not performed.
Time frame: 24 Weeks or 48 Weeks (depending on duration of treatment, which was either 24 or 48 weeks)
Number of Participants Who Achieved Sustained Biochemical Response (SBR)
Treatment duration for genotype 1 participants was 48 weeks. Treatment duration for genotypes 2 \& 3 participants who had baseline hepatitis c virus ribonucleic acid \[HCV-RNA\] \<800,000 IU/mL was 24 weeks. SBR was defined as the presence of normal alanine aminotransferase (ALT) values at the end of 24 weeks follow-up (week 48 or 72). The study was terminated due to low enrollment. This analysis was not performed.
Time frame: Week 48 or Week 72 (depending on duration of treatment, which was either 24 or 48 weeks)
Number of Participants Experiencing Opportunistic Infection
The study was terminated due to low enrollment. This analysis was not performed.
Time frame: Throughout the study (up to 72 weeks)
Number of Participants Who Died
Time frame: Throughout the study (up to 72 weeks)
Number of Participants Experiencing Adverse Events
An adverse event was defined as any untoward medical occurrence in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, which did not necessarily have a causal relationship with the treatment.
Time frame: Throughout the study (up to 72 weeks)
| Milestone | PEG-IFN + RBV |
|---|---|
| Started | 11 |
| Completed | 0 |
| Not completed | 11 |
Treatment duration for genotype 1 participants was 48 weeks. Treatment duration for genotypes 2 \& 3 participants who had baseline hepatitis c virus ribonucleic acid \[HCV-RNA\] \<800,000 IU/mL was 24 weeks. SVR was defined as plasma HCV RNA level below lower level of quanitation at the end of 24 weeks follow-up (week 48 or 72). The study was terminated due to low enrollment. This analysis was not performed.
No measurements were reported for this outcome.
Treatment duration for genotype 1 participants was 48 weeks. Treatment duration for genotypes 2 \& 3 participants who had baseline hepatitis c virus ribonucleic acid \[HCV-RNA\] \<800,000 IU/mL was 24 weeks. The study was terminated due to low enrollment. This analysis was not performed.
No measurements were reported for this outcome.
The study was terminated due to low enrollment. This analysis was not performed.
No measurements were reported for this outcome.
Treatment duration for genotype 1 participants was 48 weeks. Treatment duration for genotypes 2 \& 3 participants who had baseline hepatitis c virus ribonucleic acid \[HCV-RNA\] \<800,000 IU/mL was 24 weeks. SBR was defined as the presence of normal alanine aminotransferase (ALT) values at the end of 24 weeks follow-up (week 48 or 72). The study was terminated due to low enrollment. This analysis was not performed.
No measurements were reported for this outcome.
| participants | PEG-IFN + RBV |
|---|---|
| Number of Participants Who Died | 0 |
An adverse event was defined as any untoward medical occurrence in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, which did not necessarily have a causal relationship with the treatment.
| participants | PEG-IFN + RBV |
|---|---|
| Number of Participants Experiencing Adverse Events | 10 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PEG-IFN + RBV | — | 1/11 (9.1%) | 10/11 (90.9%) |
| Event | PEG-IFN + RBV |
|---|---|
| AnemiaBlood and lymphatic system disorders | 1/11 |
| Event | PEG-IFN + RBV |
|---|---|
| Influenza like illnessGeneral disorders | 7/11 |
| GastritisGastrointestinal disorders | 6/11 |
| AnemiaBlood and lymphatic system disorders | 2/11 |
| DiarrheaGastrointestinal disorders | 2/11 |
| Skin infectionInfections and infestations | 2/11 |
| DizzinessNervous system disorders | 2/11 |
| DepressionPsychiatric disorders | 2/11 |
| AnxietyPsychiatric disorders | 2/11 |
| InsomniaPsychiatric disorders | 2/11 |
| VertigoEar and labyrinth disorders | 1/11 |
| Age, Categorical(Participants) | PEG-IFN + RBV |
|---|---|
| <=18 years | 0 |
| Between 18 and 65 years | 11 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | PEG-IFN + RBV |
|---|---|
| Female | 0 |
| Male | 11 |
| Region of Enrollment(participants) | PEG-IFN + RBV |
|---|---|
| Indonesia | 11 |
No study locations are listed for this record.
Plan to share: Yes — http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf http://engagezone.msd.com/ds_documentation.php
No publications or documents are linked to this record.
The record gives a start of Dec 2005, a primary completion of Sep 2008 and a completion of Sep 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2012, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Peginterferon alfa-2b · Ribavirin